F00.1 F00.2 F10.2 F11.2 F12.2 F13.2 F14.2 F15.2 F16.2 F18.2 F19.2 F20.0 F20.1 F20.2 F20.3 F20.4 F20.5 F20.6 F21 F22.0 F22.8 F22.9 F25.1 F31.0 F31.3 F31.4 F31.5 F32.0 F32.1 F32.2 F32.3 F32.8 F32.9 F33.0 F33.1 F33.2 F33.3 F33.4 F33.8 F33.9 F34.0 F34.1 F34.8 F34.9 F38.0 F38.1 F38.8 F40.0 F40.1 F40.2 F40.8 F40.9 F41.0 F41.1 F41.2 F41.3 F41.8 F41.9 F43.0 F43.1 F43.2 F43.8 F43.9 F45.0
Conditions
Interventions
Group 1: In the interest of health service research within the scope of this prospective observational study following groups will be compared at 3 timepoints (beginning and end of hospital stay and 6
Sponsors
Universität Potsdam; Professur für Sozial- und Präventivmedizin
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Study participants must fulfil ICD-10 criteria for above mentioned mental disorders, be willing and able to provide informed consent, have the ability to answer questionnaires in german. These criteria are checked by an independent physician.
Exclusion criteria
Exclusion criteria: We will exclude persons who currently meet the criteria of a manic episode (ICD-10: F30.1; F30.2; F30.3; F30.8; F30.9; F31.1; F31.2; F31.6) or comorbid fulfil the criteria of the following diseases: - emotionally unstable personality disorders (ICD-10: F60.3x) - other personality and behavioral disorders (ICD-10: F61-F69) - intelligence disorders (ICD-10 F70-F79)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnosis-specific disease severity: patient group, measure of disease severity F0: Montreal Cognitive Assessment (MoCA) F1: Alcohol, Smoking and Substance Involvement Screening Test (WHO ASSIST), Severity of dependence scale (SDS), Visual Analog Scale for Craving (VAS) F2: Eppendorfer Schizophrenia-Inventory (ESI) F3: BDI-II F4: Depression anxiety stress scale(DASS), Patient Health Questionnaire (PHQ-15 - somatoform disorder), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5 - PTSD) | — |
Secondary
| Measure | Time frame |
|---|---|
| MINI-RDoC: cross-diagnostic psychological-behavioural signatures of mental disorders according to the principle of research domain criteria (RDoC) proposed by the National Institute of Mental Health (NIMH) in the dimensions of positive and negative valence system, cognition, regulatory systems and social processes using validated questionnaires and neuropsychological tests: Clinical Global Impression (CGI); Brief Symptom Inventory (BSI-53); Positive and Negative Affect Scale (PANAS); Emotion Regulation Questionnaire (ERQ); Behavioral approach/behavioral inhibition scale (BIS/BAS); Barret impulsivity scale (BIS; early childhood traumatic experiences (CTS); Trailmaking Test A and B (cognitive processing speed; executive function); Number Symbol Test (attention, cognitive processing speed); Vocabulary Test (pre-morbid IQ) , number span forward (working memory/short term memory), sleep (PSQI), functional level (WHO DAS 2.0 /WHO-Disability Assessment Schedule Degree of limitation of everyday skills), quality of life (WHO-5) Psychopharmacotherapy: drug class (antidepressants, antipsychotics, sedative, hypnotics, stimulants etc.), dosage and side effects. Process variables: amount and duration and kind of therapy used described byTIDieR-Checklist (Template for Intervention Description and Replication), mindfulness (FFMQ), patient satisfaction (ZUF-8), personal recovery and use of health system after the hospital stay | — |
Countries
Germany
Contacts
Public ContactAnna Rezo
Universität Potsdam
Outcome results
None listed